Additional information
| Active substance | Trastuzumab |
|---|---|
| Acne | No |
| Water Retention | No |
| HBR | No |
| Hepatotoxicity | No |
| Aromatization | No |
| Lab Test | HER2 testing (immunohistochemistry or fluorescence in situ hybridization) |
| Also known as | rhuMAb HER2 |
| WAREHOUSE | International Warehouse 2 |
| Blood pressure | Can cause hypertension |
| Trade name | Herceptin |
| Storage conditions | Store refrigerated at 2-8В°C (36-46В°F) |
| Chemical name | Trastuzumab |
| Formula | C6484H9996N1720O2014S44 |
| Substance class | Monoclonal antibody |
| Main action | HER2/neu receptor antagonist |
| Half-life | Approximately 28 days |
| Dosage (medical) | Typically 4 mg/kg as a loading dose followed by 2 mg/kg weekly or 6 mg/kg every three weeks |
| Dosage (sports) | Not applicable |
| Effects | Reduction in tumor growth, improved survival in breast cancer patients |
| Side effects | Fever, nausea, vomiting, infusion reactions, cardiotoxicity |
| Use in sports | None |
| Manufacturer | Roche |
Balkan Pharma Danabol 10 mg 100 Tabletten
Norvacs 5 mg Pfizer
Januvia 100mg Merckgroup
Champix 56 tabs Pfizer
Avory Pharma Winstrol 10mg 100 Kapseln
Zimaks 400 Bilim
Seretide Disckus (Advair) 250 mcg Glaxosmithkline
AVELOX 400 Bayer
Balkan Pharma Danabol 50 mg 60 Tabletten 

Reviews
There are no reviews yet.